Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.58 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR7 | P34969 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667888 | 1.00 | FAAH (0.58) | FAAHDAGLACES1HTR1ADRD2 | |
| SCHEMBL30093447 | 0.92 | DRD2 (0.62) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL1668218 | 0.92 | DRD2 (0.62) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL3752137 | 0.92 | DRD2 (0.62) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL28919882 | 0.92 | DRD2 (0.62) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL28919881 | 0.91 | DRD2 (0.63) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| Bromide SCHEMBL28956727 | 0.90 | DRD2 (0.62) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL19043117 | 0.87 | DRD2 (0.61) | HTR1ADRD2HTR7SLC6A4HTR2A | |
| SCHEMBL8922993 | 0.83 | FAAH (0.50) | FAAHDAGLACES1NPC1HPGD | |
| SCHEMBL12548965 | 0.81 | NPC1 (0.63) | HTR1ADRD2HTR7SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| US-7560570-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-10-27 | — | — | US | disclosed |
| US-6891043-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE | 2003-05-15 | — | — | US | disclosed |
| US-6462054-B1 | ALPHA KETO HETEROCYCLIC PHARMACOPHORE; COMPLEMENTARY BINDING BY ELECTROPHILIC CARBONYL AND WEAKLY BASIC NITROGEN OF SUCH AS OXAZOLOPYRIDINE GROUP; SLEEP AIDS OR ANALGESICS; PRESERVING ENDOGENOUS LEVELS OF OLEAMIDE AND ANANDAMIDE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | FAAH 406/4885DAGLA 4112/4885CES1 59/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | FAAH 407/4885DAGLA 4120/4885CES1 61/4885 |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 131/4885CES1 23/4885 |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 202/4885CES1 9/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | FAAH 405/4885DAGLA 4551/4885CES1 155/4885 |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 131/4885CES1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.